Annette Marie Maznyczka, Peter McCartney, Patrycja Duklas, Margaret McEntegart, Keith G Oldroyd, John P Greenwood, Douglas Muir, Saqib Chowdhary, Anthony H Gershlick, Clare Appleby, Hany Eteiba, James Cotton, Andrew Wragg, Nick Curzen, R Campbell Tait, Peter MacFarlane, Paul Welsh, Naveed Sattar, Mark C Petrie, Ian Ford, Keith A A Fox, Alex McConnachie, Colin Berry
OBJECTIVES: Persistently impaired culprit artery flow (<TIMI 3) during primary percutaneous coronary intervention is a surrogate for failed myocardial perfusion. We evaluated the effects of intracoronary alteplase according to TIMI flow grade immediately preceding drug administration. METHODS: In T-TIME (trial of low-dose adjunctive alTeplase during primary PCI), patients ≤6 hours from onset of ST-elevation myocardial infarction (STEMI) were randomised to placebo, alteplase 10 mg or alteplase 20 mg, administered by infusion into the culprit artery, pre-stenting...
January 12, 2021: Heart